Global and Japan Tumor Genomics Market Size, Status and Forecast 2021-2027

Tumor genomics, also known as cancer genomics, is an emerging sub-discipline in genomics, mainly through the high-throughput sequencing technology to associate genes with cancer. Tumor is a disease caused by the accumulation of DNA mutations that leads to an uncontrolled proliferation of cells and the formation of new organisms. The main goal of tumor genomics is to provide new methods for tumor diagnosis, tumor clinical outcome prediction and tumor target treatment by identifying new oncogenes or tumor suppressor genes.

Market Analysis and Insights: Global Tumor Genomics Market
The global Tumor Genomics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Tumor Genomics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Tumor Genomics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Tumor Genomics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Tumor Genomics market.

Global Tumor Genomics Scope and Market Size
Tumor Genomics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Tumor Genomics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Assays and Kits
Instrument

Segment by Application
Diagnostics and Monitoring
Drug Discovery and Development
Biomarker Discovery

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Abbott Laboratories
Agilent Technologies, Inc
Bio-Rad Laboratories, Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd
Fluidigm Corporation
General Electric Company
Illumina, Inc.
Merck KGaA
Myriad Genetics, Inc.
Pacific Biosciences of California, Inc.
PerkinElmer
QIAGEN
Siemens Healthineers AG
Thermo Fisher Scientific Inc.

Frequently Asked Questions